The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

As the global markets navigate a complex landscape marked by volatile tech stocks, geopolitical tariff tensions, and shifting ...

CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if ...

Novartis AG (NVS) stock saw a modest uptick, ending the day at $105.48 which represents a slight increase of $0.76 or 0.73% from the prior close of $104.72. The stock opened at $104.47 and touched a ...

Novartis AG's ( VTX:NOVN ) dividend will be increasing from last year's payment of the same period to $3.50 on 13th ...

Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on ...

Novartis has become the latest drugmaker to get in trouble over an employee’s LinkedIn likes. The U.K. | Novartis has become ...

Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug ...

Deutsche Bank upgraded Novartis (NVS) to Buy from Hold with a price target of CHF 110, up from CHF 100. The firm says the company’s ...

The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...

Novartis AG said profit will rise this year as new medicines help offset competition from copycats of its best-selling drug, ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...